Trilaciclib Increases Pool of Memory T Cells in the Tumor Microenvironment Responsible for Long Term Immune Surveillance and Efficacy
04 juin 2023 07h13 HE
|
G1 Therapeutics
- Phase 2 Mechanism of Action Trial Results Demonstrate the Immunomodulatory Effects of Trilaciclib in the Tumor Microenvironment - - Trilaciclib Enhances Expression of Genes Associated with Memory T...
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 juin 2023 16h40 HE
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., June 01, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options...
G1 Therapeutics Announces Appointment of Monica Thomas as General Counsel
22 mai 2023 16h45 HE
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., May 22, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the appointment of Monica Thomas as its...
New Study Confirms Consistent Risk of Myelosuppression Across All Patients Receiving Chemotherapy for Small Cell Lung Cancer
16 mai 2023 07h30 HE
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., May 16, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today described recently presented real-world data that...
New Results from Phase 2 Trial Confirm Benefit of Trilaciclib in Reducing Adverse Events Related to an Antibody Drug Conjugate (ADC)
10 mai 2023 07h31 HE
|
G1 Therapeutics
- On-Target Effect of Trilaciclib Reduces Rates of Multiple Adverse Events Associated with Sacituzumab Govitecan-Hziy by Over 50% Including Neutropenia, Anemia, and Diarrhea - - Most Enrolled...
G1 Therapeutics Provides First Quarter 2023 Financial Results and Operational Highlights
03 mai 2023 06h30 HE
|
G1 Therapeutics
- Drove 18% Quarterly Net Revenue Growth of COSELA® (trilaciclib) Over the Fourth Quarter of 2022; Grew Quarterly Vial Volume by 21% Over Prior Quarter - - Provided Updated Timing for Interim Overall...
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 mai 2023 17h00 HE
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., May 01, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options...
G1 Therapeutics to Release First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023
26 avr. 2023 12h45 HE
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., April 26, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a...
G1 Therapeutics to Participate in the 22nd Annual Needham Virtual Healthcare Conference
11 avr. 2023 12h30 HE
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., April 11, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1’s Chief Executive Officer Jack...
G1 Therapeutics Provides Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
01 mars 2023 06h30 HE
|
G1 Therapeutics
- Achieved $31.3 Million in Net Revenue from Sales of COSELA® (trilaciclib) for Full Year 2022, Representing 182% Growth Over 2021; Provided 2023 Net COSELA Revenue Guidance of $50 to $60 Million - -...